A multicenter phase II study of cabozantinib + nivolumab for patients with advanced angiosarcoma previously treated with a taxane (Alliance A091902)
- Citation:
- J Clin Oncol vol 41 (suppl 16) 11503
- Meeting Instance:
- ASCO 2023
- Year:
- 2023
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Preliminary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U24CA196171; U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG);
- Corr. Author:
- Authors:
- Juneko E. Grilley Olson Jacob Allred Scott Schuetze Andrew Poklepovic Michael J. Wagner Blake T Waechter Richard F. Riedel Meng Xu-Welliver Stephanie Berg Suzanne George Steven Robinson Paul Googe Sandra P. D'Angelo Gary Schwartz
- Networks:
- COLUMBIA, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NC010, LAPS-NY016, VCU
- Study
- Alliance-A091902
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: